Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
it is def beat down. hoping for a run to at least .005, will begin peeling off shares at .0035 just to capture some profits
hopefully someday this platform gets bought out by Elon Musk like twitter was to expose the corruption taking place in the market and expose platforms who censor the the truth & spew lies to obfuscate the transparency which is needed to make sound market decisions.
my hope is that a lawsuit would follow and the trillions of dollars stolen from honest investors would be recompensed.
and the liars who deceived investors would be sentenced to life in prison. that is the only way to curtail the economic terrorism taking place on platforms and in the market. this post is intended for: if the shoe fits
watch this video on Ai and Robotics
This Stock has all the makings for a run to Dollar Land $$$
f.u.d. buy the dips!!
DLOC ready to run, get in asap....0012 could run to .01+
runner? volume picking up!!!
Volume is Stellar!!! institutions are covering!! ready to fly imo
GLTA
options strike at .50 cents, lots of volume, this thing can really make a comeback.
looking pretty good to me!!! Shorts are covering this beat down ole doggy. time to go really long!!! $46 buy out maybe.............?
Once a deficiency notice has been sent, the company has 90 days to comply with the continued listing standards, or 180 days if the violation was for a sub-$1.00 share price. In order to be compliant, the company's share price or market cap must rise above the minimum for at least 10 consecutive days in the 90-day (or 180-day) period.
I'm hoping this will blow past 1.20 this coming week !!!
You Called it!!!! What Sheisters!!!
def not me!!! probably an m&m !!!! way to ruin a nice little run :*(
This stock is primed to move up!!! O/S only 400+ million. very low for otc. was once trading at 2.50/share.
the shorts will begin to cover soon or get burned. All rallies begin with the Shorts(buying to cover) Covering their positions!!!
now is the time to buy!!!
slap that Ask!!! going to at least .0026
PR sends this ......holding!!!
this quiet little stock is set to run!!!
The baker Brothers increased their position recently. hmmmm.....
http://www.j3sg.com/Reports/Stock-Insider/Generate-Institution-Portfolio.php?institutionid=4698&DV=yes&position=3&viewArchive=no&archiveDateIn=
looks like over 6000 bay area (San Fran) will be getting pink slips and losing their jobs. i guess they will know how it feels now like all the people in the oil and coal industries felt. life is full of surprises, i guess you could say this is the boomerang affect.
That is good to know!! a good Army friend of mine who I served with in the 1st gulf war was recently diagnosed with LGL a rare blood cancer/Luekemia. VA kept wanting to send him to Mental Health, He got an outside Doctor who did a special blood test on him and that is when they found it. When he brought the results back to VA, the dr's were like "wow, you actually do have something wrong with you", and STILL wanted to send him to Mental Health!!! UNBELIEVABLE!!! Anyhow, I do believe Enzolytics will eventually be able to identify and treat most blood cancers and auto imune diseases. I have been in this stock since it was trading at .0036. I am Long and strong and believe in this Company. I also believe politically they have a lot of opposition from the entrenched establishment who are not too fond of the change this company will bring. It is time for a change of guard!!! Nov 3 will be the beginning of change imo. Vietnam Veterans and Gulf War Veterans deserve more than the way they are being gaslighted by the VA. We Need ENZC
https://my.clevelandclinic.org/health/diseases/24128-large-granular-lymphocytic-leukemia#diagnosis-and-tests
watch this video it is about Gulf War Illness being caused by Sarin Gas.
Dr Robert Haley of the University of Texas who discovered the link to Saran Gas is being visited by a Gulf War Veteran who is trying to bring awareness to the forgotten war veterans who are ill and written off by US Government.
I am hoping ENZC can help somehow.
please forward this to get the word out and raise awareness for thhose of us veterans stricken by Gulf War Ilness. Thank you!!!
Chargepoint should aquire VNTH
I agree Maga!!! Enzolytic's silence is Golden!! this Bio-technology is a game changer!!!
I cant wait for official lift off!! it is going to be Stellar!!!
The Shorts have had their time, now it is the Longs Turn.
"ALL RALLIES BEGIN WITH THE SHORTS COVERING"
tomorrow is the 2 year anniversary since merger of bioclonetics & Enzolytics.
Charles is going to drop something, hopefully the mother of all PR's!!!!
this will shoot straight up like a space X rocket!!!
Something is brewing ..... hmmm
Shorts could get burned really bad here..........News could drop any minute!
exciting times ahead for ENZC Longs
no, don't "sell" for peanuts, BUY to cover your position when the stock price goes to peanuts, after selling barrowed shares that opened up your short position at .08 cents!!!
this will run long and high....similar to TS*P
Question: why are people buying this when the buyout price is .015 cents/ share. how can $ be made on this trade?
i have a hunch that there is a level of politics involved in our beloved ENZC share price being crushed. This company is a huge threat to the powers that be in that they are able to use Ai to confront most any virus. Cures are not "Sustainable" and Big Pharma makes their money treating symptoms. I remember a good while back when 45 was in offjce, he let out a little blurp about all the new wonderful new medicine that offered cures for diseases, then he said, no we're not ready for for that just yet" but he was hinting to major cures that were being worked on.
this is not the one I heard, can't seem to find it in the sea of youtube videos, but he mentions erradicating Aids!!! this was 3 years ago.
think of how long we have been shorted. i believe it will be held down in order for everyone in the know to cover and not make it appear as though anything out of the usual is going on. the ground hog day analogy is fitting, but remember in the movie, there was that day when Bill Murray broke out of that pattern of Sonny and Cher. that is when the Manipulators, after having traders in a trance for so long, will say "I GOT YOU (and your precious shares) BABE"
bullcrap, it is and naked short and distort MM's and their cohorts in crime. they do it everywhere on many otc stocks and their hallmark sign is to blame the insiders, or ceo in a smear campaign!! its all par for the course!!!
we need more volume!!! News would ignite a massive rally, C'mon Charles, unleash the Kraken!!!
?
Home
Addiction
Alzheimer's Disease & Dementia
Arthritis & Rheumatism
Attention Deficit Disorders
Autism Spectrum Disorders
Biomedical Technology
Cardiology
Dentistry
Diabetes
Diseases, Conditions, Syndromes
Endocrinology & Metabolism
Gastroenterology
Genetics
Gerontology & Geriatrics
HIV & AIDS
Health
Health Informatics
Immunology
Inflammatory Disorders
Medical Economics
Medical Research
Medications
Neuroscience
Obstetrics & Gynaecology
Oncology & Cancer
Ophthalmology
Other
Overweight & Obesity
Parkinson's & Movement Disorders
Pediatrics
Psychology & Psychiatry
Radiology & Imaging
Sleep Apnea
Sports Medicine & Kinesiology
Surgery
Vaccination
Sep 29, 2022
0
Oncology & Cancer
Immunology
CAR T-cell therapy proves effective in first trial in patients with resistant multiple myeloma
by Roswell Park Comprehensive Cancer Center
?
Credit: CC0 Public Domain
A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Roswell Park Comprehensive Cancer Center report in a new study published today by the New England Journal of Medicine.
The patients were treated at MSK during the clinical trial and the CAR T cell manufacturing was performed at the institution's Cell Therapy Cell Engineering Facility (CTCEF).
"It's a novel cellular-therapy approach for multiple myeloma that, in this first small study, demonstrated a strong response rate in patients, even those who were previously treated with other CAR T calls targeted to another antigen, BCMA," says Renier Brentjens, MD, Ph.D., Deputy Director and the Katherine Anne Gioia Endowed Chair in Cancer Medicine at Roswell Park and a co-senior author on the study.
"It's a proof-of-principle study, but these results provide a rationale for not just infusing a single population of CAR T cells but using several populations that may be targeted to different proteins on the surface of the tumor cell."
The therapy, a chimeric antigen receptor (CAR) T-cell therapy, sparked remissions in 70.6% of the 17 patients in the trial, all of whom had myeloma that had relapsed or was resistant to previous therapies, report the study authors. Many of the responders had relapsed after treatment with a previous generation of CAR T-cell therapies, which target a cell antigen known as BCMA. The findings have spurred the opening of a larger trial of the new therapy, which targets an antigen known as GPRC5D, in patients with myeloma.
"CAR T-cell therapy is one of the most promising ways to treat cancer," says Sham Mailankody, MBBS, first author and principal investigator for the clinical trial at MSK. "While the clinical trial is still in early stages, we are encouraged by the results as post-treatment tests are showing that six participants had a complete response to the treatment and twelve of the patients are showing a measurable decline in their cancer."
"CAR T-cell therapies targeting BCMA [the B cell maturation antigen]—a protein prevalent on immune system B cells—have shown promise in advanced myeloma, but many patients relapse," says Eric L. Smith, MD, Ph.D., of Dana-Farber, co-senior author of the study along with Dr. Brentjens.
"We developed CAR T cells targeting an antigen that we identified—called G protein-coupled receptor, class C group 5 member D, or GPRC5D—which were effective in the laboratory against myeloma cells and in animal models of the disease, including those that no longer responded to BCMA-targeting CAR T cells. Our phase 1 study represents the first time this second-generation CAR T-cell therapy has been tested in patients."
Like most CAR T-cell therapies, the one reported in this study, and developed at MSK, is custom-made for each patient. Millions of T cells are collected from the patient's blood and equipped with a synthetic gene that lets them lock onto a specific protein on cells—in this case, the GPRC5D antigen. The genetically enhanced cells are then infused back into the patient, where they lead an attack on cells carrying the antigen.
"Our preclinical work showed GPRC5D to be an attractive target for a CAR T-cell therapy for multiple myeloma," adds Dr. Smith. "We found it to be especially abundant on myeloma cells compared to normal tissue."
The GPRC5D antigen is something of a mystery, as its role in normal cell life is unclear. Still, when researchers probed the surface of myeloma cells for proteins that were particularly plentiful, GPRC5D stood out.
The 17 patients in the phase 1 trial at MSK had undergone a median of six prior treatments for myeloma, including several who had received CAR T-cell therapy targeting BCMA. Four dose levels of the second-generation CAR T-cell therapy were tested.
The study showed the therapy to be generally safe, with side effects comparable to those associated with BCMA-directed CAR T-cell therapies. Fifteen of the participants experienced cytokine release syndrome (CRS), a common, temporary consequence of CAR T-cell treatment marked by systemic inflammation.
In all cases but one (in a patient who received the highest dose tested) CRS was mild or moderate. At the highest dose level, two patients experienced toxicity in the cerebellum of the brain. No patients died from adverse events associated with the treatment.
Post-treatment tests showed that 12 participants, representing 70.6% of the whole group, responded to the treatment, showing a measurable decline in their cancer. Six had a complete response, an absence of detectable cancer. Two of the patients are still showing a response to the therapy, more than a year after they were treated.
"We are very grateful to our patients and caregivers who participated in this early trial and are continuing to explore additional clinical trials of GPRC5D directed CART cells in combination with other promising treatments to improve outcomes for patients with this disease," adds Dr. Mailankody.
+ Explore further
Researchers report encouraging immunotherapy option for relapsed myeloma patients
More information: Sham Mailankody et al, GPRC5D-Targeted CAR T Cells for Myeloma, New England Journal of Medicine (2022). DOI: 10.1056/NEJMoa2209900
Journal information: New England Journal of Medicine
Provided by Roswell Park Comprehensive Cancer
Medications
Neuroscience
Obstetrics & gynaecology
Oncology & Cancer
Ophthalmology
Other
a Short "Realist" with one thing in mind, pump out the preverbial Fud, and cover once the shareprice is demolished!!!
what a way to make a living, crushing peoples optimism & honest Investments.
for what? to have filthy Lucre. there is a price to pay when its all said and done.
BOOM!!!!
https://www.travelandleisure.com/us-department-transportation-electric-vehicle-charging-station-expansion-6744722
DOT approved Sept 28th 2022!!!
seems very criminal in my opinion. orchestrated by a sophisticated white collar criminal Syndicate. nothing is by chance, planned way in advance. really angers an honest investor who believes in doing the best for mankind. Greed is the downfall of the Human race.